Looking for robust and validated cell lines transfected with ion channel targets? Aurora Biomed Inc. offers cell lines for purchasing and licensing for some of the most common drug discovery ion channel targets. Our cell line collection includes the hERG and Kv1.3 potassium channels, and the Nav1.5 sodium channel. Each cell line has been optimized by our assay development team to stably express the ion channel of interest, and has been validated using both flux assays and electrophysiology. The window of detection (signal/noise) of these cell lines is appropriate for high-throughput screens. These cell lines, when used with our proprietary Ion Channel Reader and optimized reagens, can help generate robust, sensitive assays for ion channel screening.
The cardiac sodium channel, Nav1.5 also known as hH1a is emerging as an important target for cardiotoxicity screening as mutations in its gene (SCN5a), contribute to a type of long-QT syndrome (LQT3). Abnormal heart rhythms due to this mutation are more likely to be fatal than those due to LQT1 (KVLQT1) or LQT2 (hERG). Moreover, there is a recent report suggesting that non-specific binding of drugs with this channel may lead to abnormal cardiac rhythms. Therefore, Nav1.5 is now being included in cardiotoxicity screening panels. Early screening of novel chemical entities (NCEs) for Nav1.5 channel activity is a vital step in the drug-discovery process.
Our HEK-Nav1.5 sodium channel cell line was developed and validated as a tool for screening such NCEs.